This generally well-conducted review concluded that intensive blood pressure lowering regimens appeared to provide protection against kidney failure events in patients with chronic kidney disease, particularly among those with proteinuria; safety remained an uncertainty. The strength of evidence did not support strong conclusions on renal outcomes and the authors conclusions may be overly strong.
Study selection
Randomised controlled trials (RCTs) with at least six months follow-up that compared intensive and standard antihypertensive regimens (classified based on target blood pressure levels) in patients with chronic kidney disease (Kidney Disease Outcomes Quality Initiative definition) were eligible for inclusion. Trials had to report incidences of kidney failure and/or cardiovascular events. The primary outcome was a composite of 50% decline in glomerular filtration rate and doubling of the serum creatinine level, or end-stage kidney disease; end-stage kidney disease was also reported as a separate outcome.
Blood pressure targets varied substantially across trials. Mean age of patients ranged from 12 to 74 years and 26% to 64% of the participants were women. Where reported, approximately one third of the studies excluded patients with diabetes and another third restricted inclusion to this subgroup.
Two reviewers independently selected studies for the review.
Assessment of study quality
Two reviewers independently assessed study quality using the Cochrane risk of bias tool.
Data extraction
Two reviewers independently extracted data to calculate hazard ratios (HR) for time dependent outcomes and mean differences for continuous outcomes, each with 95% confidence intervals (CI). Relative risks (RR) were extracted where hazard ratios were not available. Data had to be reported separately for patients with chronic kidney disease in trials with mixed populations. Differences were resolved by discussion or referral to a third reviewer. Trial authors were contacted for additional information where necessary.
Methods of synthesis
Pooled hazard ratios, risk ratios or weighted mean differences (WMD) were calculated along with their 95% CI using the DerSimonian-Laird random-effects model. Heterogeneity was assessed using the Ι² statistic. Subgroup analyses investigated the impact of baseline proteinuria. Patient age, duration of follow-up, sample size, event number, baseline glomerular filtration rate and trial quality were also investigated but this was not prespecified in the methods. Publication bias was investigated using funnel plots.
